Abcellera Biologics Inc ABCL

$12.55 +0.53 (4.41%)

Valuation

Market cap
3,933,819,000
Revenue TTM
$75,130,000
Net income TTM
$-146,410,000
PE ratio
0.00
Forward PE
—
Profit margin
-194.88%
Debt to equity
0.00

Trading

Volume
4,683,287
Avg volume
7,175,914
Day's range
$11.93 – $12.79
Shares out
306,611,000
Stochastic %K
4%
Beta
1.41
Analysts
Strong Sell
Price target
$16.70

Price

Company profile

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-medi...

Show more

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; Jazz Pharmaceuticals plc to develop T-cell engaging (TCE) multispecific antibodies; partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc.; and Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.

Industry
Biotechnology
Sector
Healthcare
Phone
604 559 9005
Website
https://www.abcellera.com
Address
150 W 4th Avenue, Vancouver, Canada

Latest news

Stocktwits

erpy Oct 9, 4:06 PM
$ABCL Still going higher jmho.. Holding every share. Insiders recently loaded it wasnt for $12.5 jmho
0 replies
Ripvip Oct 9, 3:27 PM
$ABCL partnerships !
2 replies
erpy Oct 9, 1:41 PM
$ABCL Coming Data... yum
0 replies
Stockingtrade Oct 9, 12:35 PM
$ABCL New presentation! I’m sensing a big bounce off 12 today - no one who has been watching this stock is selling it in volume now, and the institutions are going to add at this price point. Here we go!!
0 replies
Planetpaprika Oct 9, 11:24 AM
$ABCL yesterday announced an upcoming poster presentation of Phase 1/2 data on ABCL635 at The Menopause Society’s (TMS) 2026 Annual Meeting, to be held October 20 to 24 at the Hilton Bayfront in San Diego, California. Details on AbCellera’s poster presentation at TMS are as follows: Title: Safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of ABCL635, an NK3R monoclonal antibody antagonist for the treatment of vasomotor symptoms: a Phase 1/2 study Poster ID: P-92 Date and Time: Thursday, October 22 from 6:15 p.m. to 7:15 p.m. PDT Location: Indigo Exhibit Hall (Level 2), Hilton Bayfront AbCellera will present safety, pharmacokinetics, pharmacodynamics, and efficacy data from its Phase 1/2 trial. This includes new safety data from the Phase 1 multiple ascending dose study, as well as new patient-reported outcome data from the Phase 2 study. https://investors.abcellera.com/news/news-releases/2026/AbCellera-Announces-Presentation-of-Phase-12-Data-for-ABCL635-at-TMS-2026-Annual-Meeting/default.aspx
0 replies
TraderinNYC Oct 9, 11:13 AM
$ABCL felt like an idiot adding yesterday, maybe it will pay off?
3 replies
SultanK Oct 9, 5:08 AM
$ABCL https://investors.abcellera.com/news/news-releases/2026/AbCellera-Announces-Presentation-of-Phase-12-Data-for-ABCL635-at-TMS-2026-Annual-Meeting/default.aspx
0 replies
Ripvip Oct 8, 11:33 PM
$ABCL I added. Lots
0 replies